Does IL-17 suppress tumor growth?

Blood

Volumn 115, Issue 12, 2010, Pages 2554-2555

  Ngiow, Shin Foong ^a,b   Smyth, Mark J ^a,b   Teng, Michele W L ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ADAPTIVE IMMUNITY; CANCER CELL CULTURE; CELL DIFFERENTIATION; GROWTH INHIBITION; LETTER; LYMPHOCYTE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 77950582668     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-254607     Document Type: Letter

References (6)

1. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs. 2009;10(6):543-549.
2. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood. 2009;114(2):357-359.
3. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206(7):1457-1464.
4. Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15(9):1016-1022.
5. Xiao M, Wang C, Zhang J, Li Z, Zhao X, Qin Z. IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. (Erratum in: Cancer Res. 2009;69(13):5618.) Cancer Res. 2009;69(5):2010-2017.
6. Gilfillan S, Chan CJ, Cella M, et al. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med. 2008;205(13):2965-2973.